ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.

about

ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q48155231

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.

@en

ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.

@nl

type

Item

label

ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.

@en

ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.

@nl

prefLabel

ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.

@en

ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.

@nl

P1476

ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.

@en

P2093

Angela Michelutti

http://www.w3.org/2001/XMLSchema#string

Renato Fanin

http://www.w3.org/2001/XMLSchema#string

P2860

Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.

Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity.

Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.

Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.

Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.

P304

4934-4935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.31037

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Mario Tiribelli

Daniela Damiani

P577

2017-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29053186

http://www.w3.org/2001/XMLSchema#string

P921

overexpression